Leptin (from Greek λεπτός leptos, "thin"), the "satiety hormone", is a hormone made by fat cells, which regulates the amount of fat stored in the body. It does this by adjusting both the sensation of hunger, and adjusting energy expenditures. Hunger is inhibited (satiety) when the amount of fat stored reaches a certain level. Leptin is then secreted and circulates through the body, eventually activating leptin receptors in the arcuate nucleus of the hypothalamus. Energy expenditure is increased both by the signal to the brain, and directly via leptin receptors on peripheral targets. The effect of leptin is opposite to that of ghrelin, the "hunger hormone". Ghrelin receptors are on the same brain cells as leptin receptors, so these cells receive competing satiety and hunger signals. Leptin and ghrelin, along with many other hormones, participate in the complex process of energy homeostasis.
Although regulation of fat stores is deemed to be the primary function of leptin, it also plays a role in other physiological processes, as evidenced by its multiple sites of synthesis other than fat cells, and the multiple cell types beside hypothalamic cells that have leptin receptors. Many of these additional functions are yet to be defined.
In 1950, a non-obese mouse colony being studied at the Jackson Laboratory produced a strain of obese offspring, suggesting that a mutation has occurred in a hormone regulating hunger and energy expenditure. Mice homozygous for the so-called ob mutation (ob/ob) ate voraciously and were massively obese. In the 1960s, a second mutation causing obesity and a similar phenotype was identified by Douglas Coleman, also at the Jackson Laboratory, and was named diabetes (db), as both ob/ob and db/db were obese. In 1990 Rudolph Leibel and Jeffrey M. Friedman reported mapping of the ob gene. Consistent with Coleman’s and Leibel's hypothesis, several subsequent studies from Leibel's and Friedman’s labs and other groups confirmed that the ob gene encoded a novel hormone that circulated in blood and that could suppress food intake and body weight in ob and wild type mice, but not in db mice. In 1994, Friedman's laboratory reported the identification of the gene. In 1995, Jose F. Caro's laboratory provided evidence that the mutations in the mouse ob gene did not occur in humans. Furthermore since ob gene expression was increased, not decreased, in human obesity, it suggested resistance to leptin to be a possibility. At the suggestion of Roger Guillemin, Friedman named this new hormone "leptin" from the Greek lepto meaning thin. Leptin was the first fat cell-derived hormone to be discovered. Subsequent studies in 1995 confirmed that the db gene encodes the leptin receptor, and that it is expressed in the hypothalamus, a region of the brain known to regulate the sensation of hunger and body weight.
The discovery of leptin also is documented in a series of books including Fat: Fighting the Obesity Epidemic by Robert Pool,The Hungry Gene by Ellen Ruppel Shell, and Rethinking Thin: The New Science of Weight Loss and the Myths and Realities of Dieting by Gina Kolata.Fat: Fighting the Obesity Epidemic and Rethinking Thin: The New Science of Weight Loss and the Myths and Realities of Dieting review the work in the Friedman laboratory that led to the cloning of the ob gene, while The Hungry Gene draws attention to the contributions of Leibel.
Location of gene and structure of hormone
The Ob(Lep) gene (Ob for obese, Lep for leptin) is located on chromosome 7 in humans. Human leptin is a 16 kDa protein of 167 amino acids
A human mutant leptin was first described in 1997, and subsequently six additional mutations were described. All of those affected were from Eastern countries; and all had variants of leptin not detected by the standard immunoreactive technique, so leptin levels were low or undetectable. The most recently described eighth mutation reported in January 2015, in a child with Turkish parents, is unique in that it is detected by the standard immunoreactive technique, so leptin levels are elevated; but the leptin does not turn on the leptin receptor, so the patient has functional leptin deficiency. These eight mutations all cause extreme obesity in infancy, with hyperphagia.
A nonsense mutation in the leptin gene that results in a stop codon and lack of leptin production was first observed in mice in 1950. In the mouse gene, arginine-105 is encoded by CGA and only requires one nucleotide change to create the stop codon TGA. The corresponding amino acid in humans is encoded by the sequence CGG and would require two nucleotides to be changed in order to produce a stop codon, which is much less likely to happen.
A Human Genome Equivalent (HuGE) review in 2004 looked at studies of the connection between genetic mutations affecting leptin regulation and obesity. They reviewed a common polymorphism in the leptin gene (A19G; frequency 0.46), three mutations in the leptin receptor gene (Q223R, K109R and K656N) and two mutations in the PPARG gene (P12A and C161T). They found no association between any of the polymorphisms and obesity.
A 2006 study found a link between the common LEP-4548 G/A phenotype and morbid obesity in Taiwanese aborigines, but a 2014 meta-analysis did not, however, this polymorphism has been associated with weight gain in patients taking antipsychotics.
The LEP-2548 G/A polymorphism has been linked with an increased risk of prostate cancer, gestational diabetes, and osteoporosis.
Other rare polymorphisms have been found but their association with obesity are not consistent.
A single case of a homozygous transversion mutation of the gene encoding for leptin was reported in January 2015. It leads to functional leptin deficiency with high leptin levels in circulation. The transversion of (c.298G → T) changed Aspartic acid to Tyrosine at position 100 (p.D100Y). The mutant leptin could neither bind to nor activate the leptin receptor in vitro, nor in leptin-deficient mice in vivo. It was found in a two year old boy with extreme obesity with recurrent ear and pulmonary infections. Treatment with metreleptin led to "rapid change in eating behavior, a reduction in daily energy intake, and substantial weight loss".
Leptin circulates in blood in free form and bound to proteins.
Leptin levels vary exponentially, not linearly, with fat mass. Leptin levels in blood are higher between midnight and early morning, perhaps suppressing appetite during the night. The diurnal rhythm of blood leptin levels may be modified by meal-timing.
In specific conditions
In humans, many instances are seen where Leptin dissociates from the strict role of communicating nutritional status between body and brain and no longer correlates with body fat levels:
Leptin level is decreased after short-term fasting (24–72 hours), even when changes in fat mass are not observed.
Leptin plays a critical role in the adaptive response to starvation.
Leptin levels are paradoxically increased in obesity.
All known leptin mutations except one are associated with low to undetectable immunoreactive leptin blood levels. The exception is a mutant leptin reported in January 2015 which is not functional, but is detected with standard immunoreactive methods. It was found in a massively obese 2-1/2 year old boy who had high levels of circulating leptin which had no effect on leptin receptors, so he was functionally leptin deficient.
A comparison of a mouse unable to produce leptin, resulting in obesity (left), and a normal mouse (right)
It is important to recognize that the terms central, primary, and direct are not used interchangeably: Central vs peripheral refers to hypothalamic vs non-hypothalamic location of action of leptin; direct vs indirect refers to whether there is no intermediary, or there is an intermediary in the mode of action of leptin; and primary vs secondary is an arbitrary description of a particular function of leptin.
Leptin acts on receptors in the hypothalamus, where it inhibits hunger by
counteracting the effects of neuropeptide Y, a potent hunger promoter secreted by cells in the gut and in the hypothalamus
counteracting the effects of anandamide, another potent hunger promoter that binds to the same receptors as THC
promoting the synthesis of α-MSH, a hunger suppressant
This appetite inhibition is long-term, in contrast to the rapid inhibition of hunger by cholecystokinin (CCK) and the slower suppression of hunger between meals mediated by PYY3-36. The absence of leptin (or its receptor) leads to uncontrolled hunger and resulting obesity. Fasting or following a very-low-calorie diet lowers leptin levels. Leptin levels change more when food intake decreases than when it increases. The dynamics of leptin due to an acute change in energy balance may be related to appetite and eventually, to food intake rather than fat stores.
It controls food intake and energy expenditure by acting on receptors in the mediobasal hypothalamus.
Leptin binds to neuropeptide Y (NPY) neurons in the arcuate nucleus in such a way as to decrease the activity of these neurons. Leptin signals to the hypothalamus which produces a feeling of satiety. Moreover, leptin signals may make it easier for people to resist the temptation of foods high in calories.
Leptin receptor activation inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP), and activates α-melanocyte-stimulating hormone (α-MSH). The NPY neurons are a key element in the regulation of hunger; small doses of NPY injected into the brains of experimental animals stimulates feeding, while selective destruction of the NPY neurons in mice causes them to become anorexic. Conversely, α-MSH is an important mediator of satiety, and differences in the gene for the α-MSH receptor are linked to obesity in humans.
Generally, leptin is thought to enter the brain at the choroid plexus, where the intense expression of a form of leptin receptor molecule could act as a transport mechanism.
Once leptin has bound to the Ob-Rb receptor, it activates the stat3, which is phosphorylated and travels to the nucleus to effect changes in gene expression, one of the main effects being the down-regulation of the expression of endocannabinoids, responsible for increasing hunger. In response to leptin, receptor neurons have been shown to remodel themselves, changing the number and types of synapses that fire onto them.
Increased levels of melatonin causes a downregulation of leptin, however, melatonin also appears to increase leptin levels in the presence of insulin, therefore causing a decrease in appetite during sleeping. Partial sleep deprivation has also been associated with decreased leptin levels.
Mice with type 1 diabetes treated with leptin or leptin plus insulin, compared to insulin alone had better metabolic profiles: blood sugar did not fluctuate so much; cholesterol levels decreased; less body fat formed.
Non-hypothalamic targets of leptin are referred to as peripheral targets, in contrast to the hypothalamic target which is the central target. Leptin receptors are found on a wide range of cell types. There is a different relative importance of central and peripheral leptin interactions under different physiologic states, and variations between species. In the periphery leptin is a modulator of energy expenditure, modulator between fetal and maternal metabolism, permissive factor in puberty, activator of immune cells, activator of beta islet cells, and a growth factor. Further, it interacts with other hormones and energy regulators: insulin, glucagon, insulin-like growth factor, growth hormone, glucocorticoids, cytokines, and metabolites.
The role of leptin/leptin receptors in modulation of T cell activity in the immune system was shown in experimentation with mice. It modulates the immune response to atherosclerosis, of which obesity is a predisposing factor.
Hyperleptinemia produced by infusion or adenoviral gene transfer decreases blood pressure in rats.
Leptin microinjections into the nucleus of the solitary tract (NTS) have been shown to elicit sympathoexcitatory responses, and potentiate the cardiovascular responses to activation of the chemoreflex.
In fetal lung, leptin is induced in the alveolar interstitial fibroblasts ("lipofibroblasts") by the action of PTHrP secreted by formative alveolar epithelium (endoderm) under moderate stretch. The leptin from the mesenchyme, in turn, acts back on the epithelium at the leptin receptor carried in the alveolar type II pneumocytes and induces surfactant expression, which is one of the main functions of these type II pneumocytes.
In mice, and to a lesser extent in humans, leptin is required for male and female fertility. Ovulatory cycles in females are linked to energy balance (positive or negative depending on whether a female is losing or gaining weight) and energy flux (how much energy is consumed and expended) much more than energy status (fat levels). When energy balance is highly negative (meaning the woman is starving) or energy flux is very high (meaning the woman is exercising at extreme levels, but still consuming enough calories), the ovarian cycle stops and females stop menstruating. Only if a female has an extremely low body fat percentage does energy status affect menstruation. Leptin levels outside an ideal range may have a negative effect on egg quality and outcome during in vitro fertilization. Leptin is involved in reproduction by stimulating gonadotropin-releasing hormone from the hypothalamus.
Immunoreactive leptin has been found in human breast milk; and leptin from mother's milk has been found in the blood of suckling infant animals.
Leptin along with kisspeptin controls the onset of puberty. High levels of leptin, as usually observed in obese females, can trigger neuroendocrine cascade resulting in early menarche. This may eventually lead to shorter stature as oestrogen secretion starts during menarche and causes early closure of epiphyses.
Leptin's ability to regulate bone mass was first recognized in 2000. Leptin can affect bone metabolism via direct signalling from the brain. Leptin decreases cancellous bone, but increases cortical bone. This "cortical-cancellous dichotomy" may represent a mechanism for enlarging bone size, and thus bone resistance, to cope with increased body weight.
Leptin receptors are expressed not only in the hypothalamus but also in other brain regions, particularly in the hippocampus. Thus some leptin receptors in the brain are classified as central (hypothalamic) and some as peripheral (non-hypothalamic).
Deficiency of leptin has been shown to alter brain proteins and neuronal functions of obese mice which can be restored by leptin injection.
In humans, low circulating plasma leptin has been associated with cognitive changes associated with anorexia, depression, and HIV.
Studies in transgenic mouse models of Alzheimer's disease have shown that chronic administration of leptin can ameliorate brain pathology and improve cognitive performance, by reducing b-amyloid and hyperphosphorylated Tau, two hallmarks of Alzheimer's pathology.
Factors that acutely affect leptin levels are also factors that influence other markers of inflammation, e.g., testosterone, sleep, emotional stress, caloric restriction, and body fat levels. While it is well-established that leptin is involved in the regulation of the inflammatory response, it has been further theorized that leptin's role as an inflammatory marker is to respond specifically to adipose-derived inflammatory cytokines.
In terms of both structure and function, leptin resembles IL-6 and is a member of the cytokine superfamily. Circulating leptin seems to affect the HPA axis, suggesting a role for leptin in stress response. Elevated leptin concentrations are associated with elevated white blood cell counts in both men and women.
Similar to what is observed in chronic inflammation, chronically elevated leptin levels are associated with obesity, overeating, and inflammation-related diseases, including hypertension, metabolic syndrome, and cardiovascular disease. While leptin is associated with body fat mass, however, the size of individual fat cells, and the act of overeating, it is interesting that it is not affected by exercise (for comparison, IL-6 is released in response to muscular contractions). Thus, it is speculated that leptin responds specifically to adipose-derived inflammation. Leptin is a pro-angiogenic, pro-inflammatory and mitogenic factor, the actions of which are reinforced through crosstalk with IL-1 family cytokines in cancer.
Taken as such, increases in leptin levels (in response to caloric intake) function as an acute pro-inflammatory response mechanism to prevent excessive cellular stress induced by overeating. When high caloric intake overtaxes the ability of fat cells to grow larger or increase in number in step with caloric intake, the ensuing stress response leads to inflammation at the cellular level and ectopic fat storage, i.e., the unhealthy storage of body fat within internal organs, arteries, and/or muscle. The insulin increase in response to the caloric load provokes a dose-dependent rise in leptin, an effect potentiated by high cortisol levels. (This insulin-leptin relationship is notably similar to insulin's effect on the increase of IL-6 gene expression and secretion from preadipocytes in a time- and dose-dependent manner.) Furthermore, plasma leptin concentrations have been observed to gradually increase when acipimox is administered to prevent lipolysis, concurrent hypocaloric dieting and weight loss notwithstanding. Such findings appear to demonstrate high caloric loads in excess of storage rate capacities of fat cells lead to stress responses that induce an increase in leptin, which then operates as an adipose-derived inflammation stopgap signaling for the cessation of food intake so as to prevent adipose-derived inflammation from reaching elevated levels. This response may then protect against the harmful process of ectopic fat storage, which perhaps explains the connection between chronically elevated leptin levels and ectopic fat storage in obese individuals.
Role in obesity and weight loss
Although leptin reduces appetite as a circulating signal, obese individuals generally exhibit a higher circulating concentration of leptin than normal weight individuals due to their higher percentage body fat. These people show resistance to leptin, similar to resistance of insulin in type 2 diabetes, with the elevated levels failing to control hunger and modulate their weight. A number of explanations have been proposed to explain this. An important contributor to leptin resistance is changes to leptin receptor signalling, particularly in the arcuate nucleus, however, deficiency of, or major changes to, the leptin receptor itself are not thought to be a major cause. Other explanations suggested include changes to the way leptin crosses the blood brain barrier or alterations occurring during development.
Studies on leptin cerebrospinal fluid (CSF) levels provide evidence for the reduction in leptin crossing the BBB and reaching obesity-relevant targets, such as the hypothalamus, in obese people In humans it has been observed that the ratio of leptin in the CSF compared to the blood is lower in obese people than in people of a normal weight. The reason for this may be high levels of triglycerides affecting the transport of leptin across the BBB or due to the leptin transporter becoming saturated. Although deficits in the transfer of leptin from the plasma to the CSF is seen in obese people, they are still found to have 30% more leptin in their CSF than lean individuals. These higher CSF levels fail to prevent their obesity. Since the amount and quality of leptin receptors in the hypothalamus appears to be normal in the majority of obese humans (as judged from leptin-mRNA studies), it is likely that the leptin resistance in these individuals is due to a post leptin-receptor deficit, similar to the post-insulin receptor defect seen in type 2 diabetes.
When leptin binds with the leptin receptor, it activates a number of pathways. Leptin resistance may be caused by defects in one or more part of this process, particularly the JAK/STAT pathway. Mice with a mutation in the leptin receptor gene that prevents the activation of STAT3 are obese and exhibit hyperphagia. The PI3K pathway may also be involved in leptin resistance, as has been demonstrated in mice by artificial blocking of PI3K signalling. The PI3K pathway also is activated by the insulin receptor and is therefore an important area where leptin and insulin act together as part of energy homeostasis. The insulin-pI3K pathway can cause POMC neurons to become insensitive to leptin through hyperpolarization.
The consumption of a high fructose diet from birth has been associated with a reduction in leptin levels and reduced expression of leptin receptor mRNA in rats. Long-term consumption of fructose in rats has been shown to increase levels of triglycerides and trigger leptin and insulin resistance, however, another study found that leptin resistance only developed in the presence of both high fructose and high fat levels in the diet. A third study found that high fructose levels reversed leptin resistance in rats given a high fat diet. The contradictory results mean that is uncertain whether leptin resistance is caused by high levels of carbohydrates or fats, or if an increase or both, is needed.
Leptin is known to interact with amylin, a hormone involved in gastric emptying and creating a feeling of fullness. When both leptin and amylin were given to obese, leptin-resistant rats, sustained weight loss was seen. Due to its apparent ability to reverse leptin reisistance, amylin has been suggested as possible therapy for obesity.
It has been suggested that the main role of leptin is to act as a starvation signal when levels are low, to help maintain fat stores for survival during times of starvation, rather than a satiety signal to prevent overeating. Leptin levels signal when an animal has enough stored energy to spend it in pursuits besides acquiring food. This would mean that leptin resistance in obese people is a normal part of mammalian physiology and possibly, could confer a survival advantage. Leptin resistance (in combination with insulin resistance and weight gain) is seen in rats after they are given unlimited access to palatable, energy-dense foods. This effect is reversed when the animals are put back on a low-energy diet. This also may have an evolutionary advantage: allowing energy to be stored efficiently when food is plentiful would be advantageous in populations where food frequently may be scarce.
Response to weight loss
Dieters who lose weight, particularly those with an overabundance of fat cells, experience a drop in levels of circulating leptin. This drop causes reversible decreases in thyroid activity, sympathetic tone, and energy expenditure in skeletal muscle, and increases in muscle efficiency and parasympathetic tone. The result is that a person who has lost weight below their natural body fat set-point has a lower basal metabolic rate than an individual at the same weight who is of that natural weight; these changes are leptin-mediated, homeostatic responses meant to reduce energy expenditure and promote weight regain as a result of fat cells being shrunken below normal size. Many of these changes are reversed by peripheral administration of recombinant leptin to restore pre-diet levels.
A decline in levels of circulating leptin also changes brain activity in areas involved in the regulatory, emotional, and cognitive control of appetite that are reversed by administration of leptin.
Leptin was approved in the United States in 2014 for use in congenital leptin deficiency and generalised lipodystrophy.
An analog of human leptin metreleptin (trade name Myalept) was first approved in Japan in 2013, and in the United States (U.S.) in February 2014. In the U.S. it is indicated as a treatment for complications of leptin deficiency, and for the diabetes and hypertriglyceridemia associated with congenital or acquired generalized lipodystrophy.
^ abZhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK et al. (May 1997). "Crystal structure of the obese protein leptin-E100". Nature387 (6629): 206–9. doi:10.1038/387206a0. PMID9144295.
^Brennan AM, Mantzoros CS (2006). "Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications". Nat Clin Pract Endocrinol Metab2 (6): 318–27. doi:10.1038/ncpendmet0196. PMID16932309.
^ abcHalaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D et al. (July 1995). "Weight-reducing effects of the plasma protein encoded by the obese gene". Science269 (5223): 543–6. doi:10.1126/science.7624777. PMID7624777.
^ abCampfield LA, Smith FJ, Guisez Y, Devos R, Burn P (July 1995). "Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks". Science269 (5223): 546–9. doi:10.1126/science.7624778. PMID7624778.
^ abPelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T et al. (July 1995). "Effects of the obese gene product on body weight regulation in ob/ob mice". Science269 (5223): 540–3. doi:10.1126/science.7624776. PMID7624776.
^ abMaffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. (November 1995). "Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects". Nat. Med.1 (11): 1155–61. doi:10.1038/nm1195-1155. PMID7584987.
^ abConsidine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. (1996). "Serum immunoreactive-leptin concentrations in normal-weight and obese humans". N. Engl. J. Med.334 (5): 292–5. doi:10.1056/NEJM199602013340503. PMID8532024.
^Dickie MM, Lane PW (1957). "Plus letter to Roy Robinson 7/7/70". Mouse News Lett. (17): 52.
^Bahary N, Siegel DA, Walsh J, Zhang Y, Leopold L, Leibel R et al. (September 1993). "Microdissection of proximal mouse chromosome 6: identification of RFLPs tightly linked to the ob mutation". Mamm. Genome4 (9): 511–5. doi:10.1007/BF00364786. PMID7906968.
^ abZhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (December 1994). "Positional cloning of the mouse obese gene and its human homologue". Nature372 (6505): 425–32. doi:10.1038/372425a0. PMID7984236.
^Leibel RL, Bahary N, Friedman JM (January 1990). "Genetic variation and nutrition in obesity: approaches to the molecular genetics of obesity". World Rev Nutr Diet.63 (1): 90–101. PMID1973864.
^Leibel RL, Bahary N, Friedman JM (January 1993). "Strategies for the molecular genetic analysis of obesity in humans". Crit Rev Food Sci Nutr.33 (4–5): 351–58. doi:10.1080/10408399309527632. PMID8357496.
^Neill US (1 October 2010). "Leaping for leptin: the 2010 Albert Lasker Basic Medical Research Award goes to Douglas Coleman and Jeffrey M. Friedman". Journal of Clinical Investigation120 (10): 3413–3418. doi:10.1172/JCI45094.
^Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R et al. (December 1995). "Identification and expression cloning of a leptin receptor, OB-R". Cell83 (7): 1263–71. doi:10.1016/0092-8674(95)90151-5. PMID8548812.
^Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ et al. (February 1996). "Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice". Cell84 (3): 491–5. doi:10.1016/S0092-8674(00)81294-5. PMID8608603.
^Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI et al. (February 1996). "Abnormal splicing of the leptin receptor in diabetic mice". Nature379 (6566): 632–5. doi:10.1038/379632a0. PMID8628397.
^Green ED, Maffei M, Braden VV, Proenca R, DeSilva U, Zhang Y et al. (August 1995). "The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7". Genome Res.5 (1): 5–12. doi:10.1101/gr.5.1.5. PMID8717050.
^Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. (1997). "Congenital leptin deficiency is associated with severe early-onset obesity in humans". Nature387 (6636): 903–8. doi:10.1038/43185. PMID9202122.
^ abcdeWabitsch M, Funcke JB, Lennerz B, Kuhnle-Krahl U, Lahr G, Debatin KM et al. "Biologically Inactive Leptin and Early-Onset Extreme Obesity". N. Engl. J. Med.372 (1): 48–54. doi:10.1056/NEJMoa1406653. PMID25551525.
^name="pmid16571841">Wang TN, Huang MC, Chang WT, Ko AM, Tsai EM, Liu CS et al. "G-2548A polymorphism of the leptin gene is correlated with extreme obesity in Taiwanese aborigines". Obesity (Silver Spring)14 (2): 183–7.
^Zhang L, Lu M, Yuan L, Lai W, Wang Y (2014). "[Association of leptin gene-2548 G/A polymorphism with obesity: a meta-analysis]". Wei Sheng Yan Jiu (in Chinese) 43 (1): 128–32. PMID24564125.
^name="pmid24564125">Zhang L, Lu M, Yuan L, Lai W, Wang Y (2014). "[Association of leptin gene-2548 G/A polymorphism with obesity: a meta-analysis]". Wei Sheng Yan Jiu (in Chinese) 43 (1): 128–32. PMID24564125.
^Templeman LA, Reynolds GP, Arranz B, San L. (April 2005). "Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.". Pharmacogenet Genomics.15 (4): 195–200. doi:10.1097/01213011-200504000-00002. PMID15864111.
^Kang SG, Lee HJ, Park YM, Choi JE, Han C, Kim YK et al. (2008). "Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain". Prog. Neuropsychopharmacol. Biol. Psychiatry32 (1): 160–3. doi:10.1016/j.pnpbp.2007.08.002. PMID17804136.
^Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J et al. (2004). "Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease". Prostate59 (3): 268–74. doi:10.1002/pros.20004. PMID15042602.
^Ye XL, Lu CF (Oct 2013). "Association of polymorphisms in the leptin and leptin receptor genes with inflammatory mediators in patients with osteoporosis.". Endocrine.44 (2): 481–8. doi:10.1007/s12020-013-9899-9. PMID23460508.
^ abcMargetic S, Gazzola C, Pegg GG, Hill RA (2002). "Leptin: a review of its peripheral actions and interactions". Int. J. Obes. Relat. Metab. Disord.26 (11): 1407–1433. doi:10.1038/sj.ijo.0802142. PMID12439643.
^Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN et al. (August 1998). "The stomach is a source of leptin". Nature394 (6695): 790–793. doi:10.1038/29547. PMID9723619.
^Kolaczynski JW, Considine RV, Ohannesian J, Marco C, Opentanova I, Nyce MR et al. (November 1996). "Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves". Diabetes45 (11): 1511–5. doi:10.2337/diab.45.11.1511. PMID8866554.
^Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF (November 1996). "Response of leptin to short-term and prolonged overfeeding in humans". J. Clin. Endocrinol. Metab.81 (11): 4162–5. doi:10.1210/jc.81.11.4162. PMID8923877.
^Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E et al. (July 1996). "Role of leptin in the neuroendocrine response to fasting". Nature382 (6588): 250–2. doi:10.1038/382250a0. PMID8717038.
^de Salles BF, Simão R, Fleck SJ, Dias I, Kraemer-Aguiar LG, Bouskela E (July 2010). "Effects of resistance training on cytokines". Int J Sports Med31 (7): 441–450. doi:10.1055/s-0030-1251994. PMID20432196.
^Hickey MS, Considine RV, Israel RG, Mahar TL, McCammon MR, Tyndall GL et al. (November 1996). "Leptin is related to body fat content in male distance runners". Am. J. Physiol.271 (5 Pt 1): E938–40. PMID8944684.
^Hickey MS, Houmard JA, Considine RV, Tyndall GL, Midgette JB, Gavigan KE et al. (April 1997). "Gender-dependent effects of exercise training on serum leptin levels in humans". Am. J. Physiol.272 (4 Pt 1): E562–6. PMID9142875.
^Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R et al. (May 1996). "Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro". Diabetes45 (5): 699–701. doi:10.2337/diabetes.45.5.699. PMID8621027.
^Dubuc GR, Phinney SD, Stern JS, Havel PJ (1998). "Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women". Metab. Clin. Exp.47 (4): 429–34. doi:10.1016/S0026-0495(98)90055-5. PMID9550541.
^Pratley RE, Nicolson M, Bogardus C, Ravussin E (1997). "Plasma leptin responses to fasting in Pima Indians". Am. J. Physiol.273 (3 Pt 1): E644–9. PMID9316457.
^Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL (February 1997). "Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels". J. Clin. Endocrinol. Metab.82 (2): 561–5. doi:10.1210/jc.82.2.561. PMID9024254.
^Wadden TA, Considine RV, Foster GD, Anderson DA, Sarwer DB, Caro JS (January 1998). "Short- and long-term changes in serum leptin dieting obese women: effects of caloric restriction and weight loss". J. Clin. Endocrinol. Metab.83 (1): 214–8. doi:10.1210/jc.83.1.214. PMID9435444.
^Chin-Chance C, Polonsky KS, Schoeller DA (2000). "Twenty-four-hour leptin levels respond to cumulative short-term energy imbalance and predict subsequent intake". J. Clin. Endocrinol. Metab.85 (8): 2685–2691. doi:10.1210/jc.85.8.2685. PMID10946866.
^Keim NL, Stern JS, Havel PJ (1998). "Relation between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women". Am. J. Clin. Nutr.68 (4): 794–801. PMID9771856.
^Mars M, de Graaf C, de Groot CP, van Rossum CT, Kok FJ (2006). "Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet". International journal of obesity (Lond)30 (1): 122–128. doi:10.1038/sj.ijo.0803070. PMID16158086.
^Lynn RB, Cao GY, Considine RV, Hyde TM, Caro JF (February 1996). "Autoradiographic localization of leptin binding in the choroid plexus of ob/ob and db/db mice". Biochem. Biophys. Res. Commun.219 (3): 884–9. doi:10.1006/bbrc.1996.0328. PMID8645274.
^Kus I, Sarsilmaz M, Colakoglu N, Kukne A, Ozen OA, Yilmaz B et al. (2004). "Pinealectomy increases and exogenous melatonin decreases leptin production in rat anterior pituitary cells: an immunohistochemical study". Physiol Res53 (4): 403–8. PMID15311999.
^Alonso-Vale MI, Andreotti S, Peres SB, Anhê GF, das Neves Borges-Silva C, Neto JC et al. (April 2005). "Melatonin enhances leptin expression by rat adipocytes in the presence of insulin". Am. J. Physiol. Endocrinol. Metab.288 (4): E805–E812. doi:10.1152/ajpendo.00478.2004. PMID15572654.
^Copinschi G (2005). "Metabolic and endocrine effects of sleep deprivation". Essential psychopharmacology6 (6): 341–7. PMID16459757.
^Ciriello J, Moreau JM (November 2012). "Systemic administration of leptin potentiates the response of neurons in the nucleus of the solitary tract to chemoreceptor activation in the rat". J. Neuroscience229: 88–99. doi:10.1016/j.neuroscience.2012.10.065. PMID23159310.
^Torday JS, Rehan VK (October 2006). "Up-regulation of fetal rat lung parathyroid hormone-related protein gene regulatory network down-regulates the Sonic Hedgehog/Wnt/beta-catenin gene regulatory network". Pediatr. Res.60 (4): 382–8. doi:10.1203/01.pdr.0000238326.42590.03. PMID16940239.
^Anifandis G, Koutselini E, Louridas K, Liakopoulos V, Leivaditis K, Mantzavinos T et al. (April 2005). "Estradiol and leptin as conditional prognostic IVF markers". Reproduction129 (4): 531–534. doi:10.1530/rep.1.00567. PMID15798029.
^Comninos AN, Jayasena CN, Dhillo WS (2014). "The relationship between gut and adipose hormones, and reproduction". Hum. Reprod. Update20 (2): 153–74. doi:10.1093/humupd/dmt033. PMID24173881.
^Zhao J, Townsend KL, Schulz LC, Kunz TH, Li C, Widmaier EP (2004). "Leptin receptor expression increases in placenta, but not hypothalamus, during gestation in Mus musculus and Myotis lucifugus". Placenta25 (8–9): 712–722. doi:10.1016/j.placenta.2004.01.017. PMID15450389.
^Moynihan AT, Hehir MP, Glavey SV, Smith TJ, Morrison JJ (2006). "Inhibitory effect of leptin on human uterine contractility in vitro". Am. J. Obstet. Gynecol.195 (2): 504–509. doi:10.1016/j.ajog.2006.01.106. PMID16647683.
^Aka N, Atalay S, Sayharman S, Kiliç D, Köse G, Küçüközkan T (2006). "Leptin and leptin receptor levels in pregnant women with hyperemesis gravidarum". The Australian & New Zealand journal of obstetrics & gynaecology46 (4): 274–277. doi:10.1111/j.1479-828X.2006.00590.x. PMID16866785.
^Casabiell X, Piñeiro V, Tomé MA, Peinó R, Diéguez C, Casanueva FF (1997). "Presence of leptin in colostrum and/or breast milk from lactating mothers: a potential role in the regulation of neonatal food intake". J. Clin. Endocrinol. Metab.82 (12): 4270–3. doi:10.1210/jcem.82.12.4590. PMID9398752.
^Matkovic V, Ilich JZ, Skugor M, Badenhop NE, Goel P, Clairmont A et al. (October 1997). "Leptin is inversely related to age at menarche in human females". J. Clin. Endocrinol. Metab.82 (10): 3239–45. doi:10.1210/jc.82.10.3239. PMID9329346.
^Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT et al. (January 2000). "Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass". Cell100 (2): 197–207. doi:10.1016/S0092-8674(00)81558-5. PMID10660043.
^ abAllison SJ, Herzog H (2006). "NPY and bone". EXS (95): 171–82. PMID16383006.
^Gordeladze JO, Reseland JE (March 2003). "A unified model for the action of leptin on bone turnover". J. Cell. Biochem.88 (4): 706–712. doi:10.1002/jcb.10385. PMID12577304.
^Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL et al. (November 2002). "Leptin regulates bone formation via the sympathetic nervous system". Cell111 (3): 305–317. doi:10.1016/S0092-8674(02)01049-8. PMID12419242.
^Martin A, David V, Malaval L, Lafage-Proust MH, Vico L, Thomas T (2007). "Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway". Endocrinology148 (7): 3419–25. doi:10.1210/en.2006-1541. PMID17431002.
^Rőszer T, Józsa T, Kiss-Tóth ED, De Clerck N, Balogh L (April 2014). "Leptin receptor deficient diabetic (db/db) mice are compromised in postnatal bone regeneration.". Cell and Tissue Research356 (1): 195–206. doi:10.1007/s00441-013-1768-6. PMID24343796.
^Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS (September 1997). "Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress". Endocrinology138 (9): 3859–3863. doi:10.1210/en.138.9.3859. PMID9275075.
^Mabuchi T, Yatsuya H, Tamakoshi K, Otsuka R, Nagasawa N, Zhang H et al. (2005). "Association between serum leptin concentration and white blood cell count in middle-aged Japanese men and women". Diabetes Metab. Res. Rev.21 (5): 441–447. doi:10.1002/dmrr.540. PMID15724240.
^Hamilton BS, Paglia D, Kwan AY, Deitel M (September 1995). "Increased obese mRNA expression in omental fat cells from massively obese humans". Nat. Med.1 (9): 953–956. doi:10.1038/nm0995-953. PMID7585224.
^Wabitsch M, Jensen PB, Blum WF, Christoffersen CT, Englaro P, Heinze E et al. (October 1996). "Insulin and cortisol promote leptin production in cultured human fat cells". Diabetes45 (10): 1435–1438. doi:10.2337/diabetes.45.10.1435. PMID8826983.
^Worm D, Vinten J, Vaag A, Henriksen JE, Beck-Nielsen H (September 2000). "The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients". Eur. J. Endocrinol.143 (3): 389–395. doi:10.1530/eje.0.1430389. PMID11022182.
^ abCaro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH et al. (20 July 1996). "Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance". Lancet348 (9021): 159–61. doi:10.1016/S0140-6736(96)03173-X. PMID8684156.
^Considine RV, Considine EL, Williams CJ, Hyde TM, Caro JF (1996). "The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations". Diabetes45 (7): 992–4. doi:10.2337/diabetes.45.7.992. PMID8666155.
^ abOswal A, Yeo G (February 2010). "Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity". Obesity (Silver Spring)18 (2): 221–9. doi:10.1038/oby.2009.228. PMID19644451.
^Vasselli JR (November 2008). "Fructose-induced leptin resistance: discovery of an unsuspected form of the phenomenon and its significance. Focus on "Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding," by Shapiro et al". Am. J. Physiol. Regul. Integr. Comp. Physiol.295 (5): R1365–R1369. doi:10.1152/ajpregu.90674.2008. PMID18784330.
^Banks WA, Farr SA, Morley JE (June 2006). "The effects of high fat diets on the blood-brain barrier transport of leptin: failure or adaptation?". Physiol. Behav.88 (3): 244–8. doi:10.1016/j.physbeh.2006.05.037. PMID16781741.